Physician profile
Amanda C Long
NPI 1376049981
$3,233.16
in general payments reported to CMS, 2019-2025
22 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $139 · 2021: $241 · 2022: $275 · 2023: $458 · 2024: $762 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,578.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,290.00 | 2020-2025 | |
| Janssen Biotech, INC. | $272.98 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.58 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Novo Nordisk INC | $235.18 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $228.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $131.24 | 2023-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $119.99 | 2023 | Epclusa |
| Lilly USA, LLC | $118.78 | 2024-2025 | Omvoh |
| Pfizer INC. | $103.17 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.75 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $72.78 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $49.19 | 2025 | Vegzelma |
| Boston Scientific Corporation | $46.66 | 2023 | Resolution 360 Clip |
| Phathom Pharmaceuticals, INC. | $38.04 | 2024-2025 | Voquezna |
| Celgene Corporation | $34.43 | 2023 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $29.58 | 2025 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.33 | 2020 | |
| Ardelyx, INC. | $21.66 | 2024 | Ibsrela |
| Sandoz INC. | $19.05 | 2024 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $18.98 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.92 | 2025 | |
| Fresenius Kabi USA, LLC | $13.75 | 2025 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.